NCT00069901已完成2 期
CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 82
- 试验地点
- 33
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
详细描述
CT-2103 is a pharmaceutical that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer. The objective of this trial is to evaluate the toxicity, estimate the response rate, progression-free survival and overall survival in patients with newly diagnosed stage III or IV ovarian or primary peritoneal carcinoma treated with CT-2103 in combination with carboplatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (33)
Loading locations...
相似试验
已完成
3 期
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)Fallopian Tube CancerPeritoneal NeoplasmsOvarian CancerNCT03740165Merck Sharp & Dohme LLC1,367
已完成
1 期
CT-2103 in Combination With Gemcitabine in Metastatic Breast CancerBreast CancerMetastatic Breast CancerNCT00270907M.D. Anderson Cancer Center13
撤回
3 期
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mLNSCLCNCT00576225CTI BioPharma
已完成
1 期
Dose-finding Study in Platinum-Resistant Ovarian CancerRecurrent Platinum-resistant Ovarian CancerNCT01653912Accenture59
已完成
1 期
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer PatientsOvarian Epithelial Cancer Stage IIIStage IV Ovarian CancerStage IV Breast CancerNCT00316407Swedish Medical Center30